Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 20/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503074 | 0.95 | ALOX5AP (0.60) | ALOX5APCYP2C9CYP3A4PTGS1 | |
| SCHEMBL3478525 | 0.93 | ALOX5AP (0.68) | ALOX5APCYP2C9CYP3A4PTGS1 | |
| SCHEMBL3469370 | 0.91 | ALOX5AP (0.68) | ALOX5APPTGS1 | |
| SCHEMBL4195053 | 0.89 | ALOX5AP (0.74) | ALOX5APCYP2C9CYP3A4 | |
| SCHEMBL4201169 | 0.89 | ALOX5AP (0.74) | ALOX5APCYP2C9CYP3A4 | |
| SCHEMBL169990 | 0.89 | ALOX5AP (0.64) | ALOX5APCYP2C9CYP3A4PTGS1 | |
| SCHEMBL4195161 | 0.87 | ALOX5AP (0.68) | ALOX5APCYP2C9CYP3A4PTGS1 | |
| SCHEMBL176137 | 0.82 | ALOX5AP (0.56) | ALOX5APCYP2C9CYP3A4PTGS1 | |
| SCHEMBL4199554 | 0.82 | ALOX5AP (0.60) | ALOX5APCYP2C9CYP3A4PTGS1 | |
| SCHEMBL3478660 | 0.81 | ALOX5AP (0.55) | ALOX5APCYP2C9CYP3A4PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232031-A1 | INJECTABLE FORMULATIONS FOR INTRA-ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | claimed |
| EP-2490689-A2 | INJECTABLE FORMULATIONS FOR INTRA- ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | Panmira Pharmaceuticals, LLC (US) | 2012-08-29 | — | — | EP | claimed |
| US-20120027842-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR ADMINISTRATION TO AN EYE | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | claimed |
| US-20110311613-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | AMIRA PHARMACEUTICAL, INC. (US) | 2011-12-22 | — | — | US | claimed |
| EP-2381945-A2 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | Amira Pharmaceuticals, Inc. (US) | 2011-11-02 | — | — | EP | claimed |
| EP-2379078-A2 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR ADMINISTRATION TO AN EYE | Amira Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | claimed |
| WO-2011049979-A2 | INJECTABLE FORMULATIONS FOR INTRA- ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| WO-2010075315-A2 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR ADMINISTRATION TO AN EYE | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | claimed |
| WO-2010075314-A2 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | claimed |
| US-9688624-B2 | DP2 antagonist and uses thereof | BRICKELL BIOTECH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-8815917-B2 | DP2 antagonist and uses thereof | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-8785393-B2 | Ophthalmic pharmaceutical compositions of DP2 receptor antagonists | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-8669289-B2 | Methods and compositions relating to hematologic malignancies | THE JACKSON LABORATORY (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130053444-A1 | DP2 ANTAGONIST AND USES THEREOF | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20110311613-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | AMIRA PHARMACEUTICAL, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011109679-A2 | INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011085033-A2 | DP2 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011049979-A2 | INJECTABLE FORMULATIONS FOR INTRA- ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110034558-A1 | DP2 Antagonist and Uses Thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| WO-2010124283-A2 | METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES | THE JACKSON LABORATORY (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034558-A1 | DP2 Antagonist and Uses Thereof | PTGER2, PTGES2, PTGDR2 | ALOX5AP 63/4885CYP2C9 2149/4885CYP3A4 2374/4885 |
| US-20120027842-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR ADMINISTRATION TO AN EYE | FEN1, SERPINB1, EYA2 | ALOX5AP 100/4885CYP2C9 4727/4885CYP3A4 4571/4885 |
| US-20110311613-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | TSLP, SUCLG1, SERPINB1 | ALOX5AP 96/4885CYP2C9 4681/4885CYP3A4 4448/4885 |
| US-20130053444-A1 | DP2 ANTAGONIST AND USES THEREOF | PTGER2, PTGDR2, PTGES2 | ALOX5AP 70/4885CYP2C9 2566/4885CYP3A4 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.